MedTrace Logo

Study of bb2121 in Multiple Myeloma

NCT02658929 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2023-01-23

No results posted yet for this study

Summary

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Conditions

Interventions

BIOLOGICAL

bb2121

bb2121

Sponsors & Collaborators

  • Genetix Biotherapeutics Inc.

    collaborator INDUSTRY

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Kristen Hege, MD · Celgene Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-22
Primary Completion
2019-07-22
Completion
2022-09-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658929 on ClinicalTrials.gov